Abstract 360P
Background
To explore the relationship between the number of reginal lymph nodes (LNs) examined and prognosis among patients with stage IA1-2 lung adenocarcinoma (LUAD) who underwent sublobar resection.
Methods
A total of 690 patients with stage IA1-2 LUAD patients from 2004-2015 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. of which 475 were grouped into 0
Results
Before PSM, the patients with more LNs examined exhibited better OS and LCSS (Figure 1A&B). The median OS for 0< LNE≤5 cohort patients was 116.0 months, that for LNE >5 was 124.0 months (p=0.012; HR: 1.472, 95%CI: 1.107-1.959). The median LCSS for two cohorts were both not reached, respectively (p=0.044; HR: 1.498, 95%CI: 1.021-2.197). After PSM, 209 pairs of patients were matched and all variables were well balanced. And comparable OS and LCSS were observed between two matched cohorts (Figure 1C&D). The median OS for 0< LNE≤5 cohort patients was 122.0 months, that for LNE >5 was 124.0 months (p=0.28; HR: 1.187, 95%CI: 0.820-1.720). The median LCSS for two cohorts were both not reached, respectively (p=0.90; HR: 0.997, 95%CI: 0.588-1.692). Univariate and multivariate cox regression analysis revealed that the number of regional (LNs) examined was not an independent risk factors for OS or LCSS (Table; p=0.126, HR: 0.767, 95%CI: 0.479-0.919; p=0.237, HR: 0.773, 95%CI: 0.503-1.185).
Conclusions
The number of regional LNs examined did not correlate with the survival prognosis for stage IA1-2 lung adenocarcinoma patients who underwent sublobar resection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Key Lab System Project of Guangdong Science and Technology Department-Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (Grant No. 2017B030314120), Project of National Natural Science Foundation (Grant Nos. 81673031, 81872510), Research Fund from Guangzhou Science and Technology Bureau (Grant No. 201704020161), High-Level Hospital Construction Project (Grant No. DFJH201801), and Guangdong Provincial People’s Hospital Young Talent Project (Grant No. GDPPHYTP201902).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
223P - Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
Presenter: Karim Fizazi
Session: e-Poster Display Session
224P - Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with localized prostate cancer: A real-world, population-based study
Presenter: Atul Batra
Session: e-Poster Display Session
225P - Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort
Presenter: Michael Fernando
Session: e-Poster Display Session
226P - Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Andrew Jensen
Session: e-Poster Display Session
227P - Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
Presenter: Ulka Vaishampayan
Session: e-Poster Display Session
228P - Symptoms and impacts of metastatic castration-resistant prostate cancer (mCRPC) among Japanese patients designated to receive Ra-223
Presenter: Hiroji Uemura
Session: e-Poster Display Session
229P - Expanding the role of supervised exercise on fatigue in prostate cancer patient receiving androgen deprivation therapy: A meta-analysis of randomized controlled trial
Presenter: Niwanda Yogiswara
Session: e-Poster Display Session
230P - Molecular profiling and clinical characteristics of Chinese patients with prostate cancer
Presenter: Ranlu Liu
Session: e-Poster Display Session
231P - Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199
Presenter: Jeffrey Goh
Session: e-Poster Display Session
232P - Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience
Presenter: Rachel Raju
Session: e-Poster Display Session